• Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP): Lab Reliability

  2026-05-27

  This article addresses persistent laboratory challenges in cell viability and gene expression assays, demonstrating how Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) (SKU R1005) delivers reproducible, low-immunogenicity results. Using scenario-driven Q&As, we provide practical, evidence-backed guidance on protocol optimization, data interpretation, and product selection for robust bioluminescent assays.

• Inhaled RNA Disrupts Tumor Collagen for Enhanced Lung Cancer

  2026-05-26

  The referenced study introduces an inhalable lipid nanoparticle platform that co-delivers mRNA encoding anti-DDR1 antibody fragments and siRNA targeting PD-L1 to lung tumors. This dual RNA therapy remodels the tumor extracellular matrix, improving T cell infiltration and immunotherapy efficacy, and represents a significant advance in overcoming barriers posed by the tumor microenvironment.

• ONX-0914 Modulates Synaptic Plasticity via Immunoproteasome

  2026-05-26

  This study reveals that chronic administration of ONX-0914, a selective immunoproteasome inhibitor, differentially affects hippocampal synaptic plasticity by modulating tetanus-evoked LTP and associated gene expression. The findings clarify the nuanced role of non-constitutive proteasomes in neural signaling, with implications for neuroinflammation and memory research.

• WM-8014: Precision KAT6A Inhibitor for Cancer Biology Resear

  2026-05-25

  WM-8014 enables highly selective, non-cytotoxic induction of oncogene-induced senescence, setting a new standard for cell cycle arrest assays in epigenetic drug discovery. This guide translates recent CRISPR-based screening advances and validated protocols into practical, reproducible workflows for advanced cancer biology research.

• Metabolomic Profiling Reveals Carbapenemase Resistance in CP

  2026-05-25

  This study applies LC-MS/MS metabolomics to discriminate carbapenemase-producing Enterobacterales (CPE) from non-resistant isolates, identifying 21 metabolite biomarkers that enable rapid classification within seven hours. The findings suggest a promising approach for accelerating resistance diagnosis and offer mechanistic insight into the metabolic adaptations underpinning carbapenem resistance.

• Luminescent ATP Cell Viability Assay Kit I: Precision for Fe

  2026-05-24

  The Luminescent ATP Cell Viability Assay Kit I empowers researchers with ultra-sensitive, rapid cell viability measurement, outperforming traditional colorimetric methods. Its streamlined, lysis-free workflow and robust compatibility with ferroptosis and cytotoxicity studies make it a trusted tool for dynamic and challenging experimental designs.

• U-73122: Precision Phospholipase C Inhibitor for Advanced As

  2026-05-23

  U-73122 stands as a benchmark phospholipase C inhibitor, enabling precise modulation of PLC signaling in applied cell signaling, cancer metastasis, and inflammation research. This article translates recent reference study breakthroughs and best practices into actionable protocols, troubleshooting advice, and strategic workflow enhancements for researchers seeking robust, reproducible results.

• PCMT1 Drives Ovarian Cancer Metastasis via Anoikis Resistanc

  2026-05-22

  Zhang et al. used a genome-wide CRISPR/Cas9 knockout screen to identify PCMT1 as a critical driver of anoikis resistance and metastatic progression in ovarian cancer. Their study elucidates the molecular interplay between PCMT1, extracellular matrix signaling, and integrin-mediated pathways, providing new insights into therapeutic targeting of metastasis.

• MLN2238: Advanced Proteasome β5 Subunit Inhibitor Workflows

  2026-05-22

  MLN2238 offers researchers a next-generation tool for dissecting proteasome β5 subunit inhibition, enabling precise modeling of proteotoxic stress and drug resistance in multiple myeloma and lymphoma. This guide translates recent mechanistic findings into optimized experimental protocols, troubleshooting, and future assay design.

• HyperScribe T7 High Yield RNA Synthesis Kit: Workflow & Insi

  2026-05-21

  The HyperScribe T7 High Yield RNA Synthesis Kit empowers researchers to generate large quantities of high-quality RNA for advanced applications like RNA interference, vaccine research, and biotinylated probe synthesis. This article delivers actionable workflow guidance, troubleshooting strategies, and contextualizes novel findings from OSCC metastasis studies to help users achieve reproducible, high-yield results.

• Scenario-Driven Optimization with HyperScribe™ T7 High Yield

  2026-05-21

  This in-depth article addresses persistent laboratory challenges in RNA synthesis workflows and demonstrates how the HyperScribe™ T7 High Yield RNA Synthesis Kit (SKU K1047) delivers reliable, high-yield transcription for diverse biomedical applications. Drawing on real-world scenarios and recent literature, the piece provides evidence-based answers to common experimental design, protocol, and vendor selection questions, empowering researchers to achieve consistency and reproducibility in cell viability, proliferation, and RNA interference assays.

• FH1 Small Molecule: Redefining Hepatocyte Maturation and Fun

  2026-05-20

  Explore how the FH1 small molecule (Catalog No. B3700) uniquely advances cultured hepatocyte function by enhancing iPS cell differentiation, with insights bridging optogenetic gene control and translational research. This article offers an in-depth, evidence-driven analysis beyond established protocols.

• ONX-0914 (PR-957): Defining the Next Era of Immunoproteasome

  2026-05-20

  Explore ONX-0914 (PR-957) as a selective immunoproteasome inhibitor, with a deep dive into its unique mechanism, translational research potential, and new insights from recent advances in proteasome biology. Unlock perspectives not found in other resources.

• ESCO2 Drives HCC Proliferation via PI3K/AKT/mTOR Pathway Act

  2026-05-19

  This study demonstrates that ESCO2, a key regulator of sister chromatid cohesion, is upregulated in hepatocellular carcinoma (HCC) and accelerates tumor cell proliferation by activating the PI3K/AKT/mTOR pathway. These findings clarify the molecular mechanism of HCC progression and point to ESCO2 as a potential therapeutic target.

• EdU Imaging Kits (Cy3): Empowering Translational S-Phase Res

  2026-05-19

  This thought-leadership article examines the transformative potential of EdU Imaging Kits (Cy3) in reshaping S-phase DNA synthesis measurement for translational researchers. Grounded in mechanistic insights—exemplified by recent studies on Drosha’s role in mesangial cell proliferation—the piece connects advances in copper-catalyzed azide-alkyne cycloaddition (CuAAC) chemistry to practical workflow improvements, competitive differentiation, and strategic guidance for cell proliferation and genotoxicity testing.

16308 records 5/1088 page Previous Next 12345 下5页 Last page